Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Reduced ADAMTS13 Activity in Correlation with Pathophysiology, Severity, and Outcome of COVID-19: A Retrospective Observational Study

Wael Hafez,1,2,8,*, Mohamad Azzam Ziade,1 Arun Arya,1 Husam Saleh,1 Sara Ali,1 Srinivasa Raghu Rao,1 Osman Fdl Alla,1 Mohamed Ali,1 Mouhamad Al Zouhbi,1 Ahmed Abdelrahman1,3

1 NMC Royal Hospital, 16th Street, Khalifa City, Abu Dhabi, United Arab Emirates
2 Medical Research Division, Department of Internal Medicine, The National Research Centre, 33 El Buhouth St, Ad Doqi, Dokki, Cairo Governorate 12622, Egypt
3 Internal Medicine Department, Zagazig School of Medicine, Zagazig, Egypt

A R T I C L E   I N F O

Article history:
Received 8 October 2021
Revised 27 January 2022
Accepted 8 February 2022

Keywords:
ADAMTS13
Thrombosis
SARS-CoV-2
Cytokine storm
COVID-19
Pneumonia
Anticoagulation

A B S T R A C T

Background: Low ADAMTS13 activity has been suggested to be an interplaying factor in the pathogenesis of COVID-19, considering that it is a thromboinflammatory disease with high risk of microthrombosis.

Objectives: The study aimed to explore the correlation between ADAMTS13 activity and the pathophysiological pathway of COVID-19.

Methods: We carried out a retrospective observational study of 87 patients with COVID-19 in NMC Royal Hospital, Abu Dhabi, UAE. ADAMTS13 activity was measured and compared with patients’ characteristics and clinical outcomes.

Results: Low ADAMTS13 activity was associated with pneumonia (p = 0.007), severity of COVID-19 (p < 0.001), and mechanical ventilation rates (p = 0.018). Death was more frequently observed among patients (5 patients) with low ADAMTS13 activity compared with normal activity (1 patient), as well as inflammatory markers. Decreased ADAMTS13 activity increased with the risk of pneumonia, severity of COVID-19, need for mechanical ventilation, and use of anticoagulants ([OR = 4.75, 95% CI 1.54–18.02, p = 0.011], [OR = 6.50, 95% CI 2.57–17.74; p < 0.001]. [OR = 4.10, 95% CI 1.29–15.82; p = 0.024], [OR = 8.00, 95% CI 3.13–22.16; p < 0.001], respectively). The low ADAMTS13 activity group had a slightly longer time to viral clearance than the normal ADAMTS13 activity group, but it was not statistically significant (20 days, 95% CI 16–27 days vs 17 days, 95% CI 13–22 days; p = 0.08; Log rank = 3.1).

Conclusions: Low ADAMTS13 activity has been linked to pneumonia, COVID-19 severity, use of anticoagulants, and need for mechanical ventilation but not to mortality. We propose rADAMTS13 as a novel treatment for severe COVID-19.

* Corresponding author: Wael Hafez, Consultant Internal Medicine, NMC Royal Hospital, 16 St, Khalifa City, Abu Dhabi, UAE, P.O. BOX 35233.Tel.: +97122035000; Mobile: +971561987354.
E-mail addresses: waeelhafez@yahoo.com, Wael.hafez@nmc.ae (W. Hafez).

Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; CAC, Coronavirus-associated coagulopathy; rADAMTS13, Recombinant ADAMTS13; TMA, Thrombotic microangiopathy; VWF, von Willebrand factor; UAE, United Arab Emirates; WPBs, Weibel-Palade bodies.

Introduction

Coronavirus disease 2019 (COVID-19) is an endemic disease that first appeared in China in December 2019. The causative organism was identified later; it is an RNA virus that belongs to the Coronavirus family and is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Lu et al., 2020).

Disease symptoms range from absence of symptoms; mild symptoms such as fever, dry cough, muscle pain; and gastrointestinal symptoms such as nausea, diarrhea, vomiting, and severe
symptoms (Rothe et al., 2020). In severe cases, the disease may deteriorate, leading to pneumonia, acute respiratory distress syndrome (ARDS), multiorgan complications, and death (Uddin et al., 2020).

Multiple studies had reported higher rates of thrombosis and coagulopathy among patients with COVID-19; it was called later Coronavirus-associated coagulopathy (CAC). The International Society of Thrombosis and Hemostasis (ISTH) has recently released the frequently observed clinical characteristics of CAC among patients with COVID-19. They included elevated D-dimer, slightly decreased platelet count, and abnormal prothrombin time (PT) (Franchini et al., 2020).

A case study of a patient with COVID-19 who developed acute portal vein thrombosis (PVT) reported abnormal coagulation tests including D-dimer, Von-Willebrand factor (VWF), and fibrinogen, and thrombosis symptoms were relieved within 48 hours after treatment with anticoagulants (La Mura et al., 2020). In addition, the prevalence of thrombotic complications among patients with COVID-19 admitted to the ICU ranged from 16%–69% according to several studies (Wool & Miller, 2021).

A study of 23 autopsies of COVID-19 deaths reported an association among CAC, vascular damage, and endothelitis (Buja et al., 2020). Another autopsy study also reported microthrombi inside small lung arteries and glomerular capillaries among COVID-19 decedents (Carsana et al., 2020). These observations highlight the importance of studying factors responsible for thrombosis in COVID-19 to imply suitable life-saving interventions.

VWF is a large multimeric prothrombin agent secreted by endothelial cells in response to systemic inflammation and also from platelets upon activation. It promotes platelet adherence, aggregation, and thrombosis (Ruggeri, 2007). The activity of VWF is regulated by a disintegrin and metalloprotease with thrombospondin motifs-13 (ADAMTS13), which is a zinc-containing metalloprotease enzyme responsible for partial cleavage of ultra-large VWF multimers (>10,000 kDa) to high molecular weight multimers (<10,000 kDa) found in the circulation (X Zheng et al., 2001) (Fujikawa et al., 2001). The cleavage of ultra-large VWF multimers by ADAMTS13 depends on shear forces or platelet attachment to VWF exposing the ADAMTS13 cleavage site (Tripodi et al., 2008) (Peyvandi et al., 2010).

Under physiological conditions, the ultra-large VWF multimers are intrinsically active and can bind strongly with glycoprotein (GP) Ibα subunit of the GPIb-IX-V complex and promote platelet recruitment to the site of injury and hemostasis. However, cleaved VWF multimers undergo structural conformational changes to bury GP Ibα binding domain within the VWF’s core B-sheet and prevent platelet aggregation (Dong et al., 2002) (Valentijn & Eikenboom, 2013) (Choi et al., 2007) (Levy et al., 2001) (López & Dong, 2005) (Siedlecki et al., 1996) (Furlan, 1996).

During acute inflammation, injured endothelial cells release the ultra-large VWF multimers (Moake & Chow, 1998) (Sugita et al., 2013) (Rietveld et al., 2019) (Obermeier et al., 2019). When the released ultra-large VWF multimers exceed the proteolytic activity of ADAMTS13, it causes accumulation of ultra-large VWF multimers and contributes to thrombosis, affecting vital organs such as the brain, heart, and kidney (Furlan & Lämmer, 2001) (Fey et al., 2007) (Arya et al., 2002) (Sporn et al., 1986). Plasma ADAMTS13 activity deficiency (<10%) caused by ADAMTS13 gene mutations or autoantibodies against ADAMTS13 results in inherited or acquired TTP. ADAMTS13 activity can be normal or somewhat decreased (>20%) in other types of thrombotic microangiopathy. In addition, it has been demonstrated that ADAMTS13 deficiency is a risk factor for the development of myocardial infarction, stroke, cerebral malaria, and preeclampsia (X. L. Zheng, 2015). COVID-19 causes a significant increase in VWF levels, which can surpass the capacity of ADAMTS13 to handle them, resulting in the production of large VWF multimers identical to TTP (Doevelaar et al., 2021). ADAMTS13 deficiency also causes ultra-large VWF multimers accumulation, leading to thrombocytopenia and microvascular thrombosis—a disorder called thrombotic thrombocytopenic purpura (TTP) (Doevelaar et al., 2021) (X. L Zheng, 2015). The majority of TTP adult patients showed decreased ADAMTS13 cleavage of ultra-large VWF multimers caused by the neutralization of ADAMTS13 by autoantibodies, usually of the immunoglobulin G (IgG) isotype, that leads to impaired ADAMTS13 function and acquired ADAMTS13 activity deficiency (Furlan et al., 1998; Sarig, 2014; Tsai & Liu, 1998). The role of the reciprocal relationship between VWF and ADAMTS13 in thrombosis prevention and hemostasis maintenance is widely studied (Levi et al., 2018). Abnormal VWF/ADAMTS13 ratio resulting from endothelial activation by inflammation was observed in ischemic stroke, myocardial infarction, cerebral malaria, sepsis, sickle cell disease, and arterial thrombosis (Gragnano et al., 2017) (Zander et al., 2015) (Ladeira et al., 2021) (Turner et al., 2006) (South & Lane, 2018) (Masias & Catalán, 2018).

The role of the interaction between VWF and ADAMTS13 in COVID-19 is not widely studied. Although studies report abnormal levels of ADAMTS13 among patients with COVID-19, these studies were mainly case reports with a small sample size. Also, they had not drawn enough explanation of the pathophysiology of CAC (Blasi et al., 2020) (Hayakawa et al., 2021).

Recently, several ADAMTS13 assays were developed to measure ADAMTS13 activity, antigen, or autoantibodies. These assays are useful for differentiation between congenital and acquired forms of TTP. In cases of acquired TTP, ADAMTS13 activity and ADAMTS13 antigens probably follow the same trend during the acute phase. Also, the measurement of ADAMTS13 activity could be a good predictor for the levels of ultra-large VWF and autoantibodies against ADAMTS13 in the plasma. However, ADAMTS13 antigen assays have less clinical utility in the cases of acquired TTP and the presence of autoantibodies, so they are not commonly used in clinical practice as they are considered quantitative and not functional assays (Starke et al., 2007) (Peyvandi et al., 2010).

ADAMTS13 activity test was considered based on the findings of initial studies from China, which reported abnormal coagulation parameters especially increased levels of fibrinogen, D-Dimer, decreased platelet count, thrombotic microangiopathies (TMA), pulmonary microvascular thrombosis, and TTP-like TMA (Tiwari et al., 2021).

TMA refers to a group of different diseases characterized by thrombocytopenia, hemolytic anemia, and microthrombosis. The main 2 prototypes of TMA are TTP and hemolytic uremic syndrome (HUS) (Saha et al., 2017). ADAMTS13 activity test is used for differential diagnosis between TTP and other forms of TMs (Kremer Hovinga et al., 2017).

This study aimed to explore the potential role of ADAMTS13 activity in the pathophysiology of COVID-19 and investigated the relationship between ADAMTS13 activity and clinical manifestation, disease severity, and outcome.

**Methods**

**Study Design and Study Population**

This study is a noninterventional retrospective study of medical records of patients with COVID-19 treated in NMC Royal Hospital, Khalifa City, Abu Dhabi, UAE from April 8, 2020 to the end of March 2020.

Included patients were positive for SARS-CoV-2 as confirmed by real-time reverse transcriptase–polymerase chain reaction (RT-PCR) assay by nasopharyngeal swabs under aseptic operation. Included patients in the study were hospitalized adult patients with COVID-19 aged 18 or above with different disease severity grades, who
had plasma ADAMTS13 activity test done, whereas those who did not undergo the test were excluded. Patients identifiers were removed during data collection process, with complete protection of patients’ privacy. This study was conducted according to the Declaration of Helsinki. The study was approved by the NMC Central scientific committee approval (NMCHC/CSC/2020/0003), NMC Regional Ethics committee (NMC/REC/A/2020/0017), and Regional Research Ethics Committee, Department of Health, Abu Dhabi, UAE (DOH/CVDC/2020/2311).

SARS-CoV-2 Nasopharyngeal PCR test

RNA was extracted from the nasopharyngeal swabs using the Xybio extraction kit (Korea). RT-PCR was performed on the Bio-Rad Cycler PCR (USA) using Solgent’s 2019-nCoV Real-Time Reverse Transcription PCR Kit, following the manufacturer’s instructions. Viral detection was done using a CFX-96 plate reader obtained from Biorad in the United States. SARS-CoV-2 detection was performed using real-time reverse transcription polymerase chain reaction (RT-PCR) analysis of 2 target genes: the open reading frame 1ab (ORF1ab) and the nucleocapsid protein (N). This approach amplifies the genetic material present in the specimen and detects the presence of the virus. The sample’s RNA is extracted and reverse transcribed to DNA. This DNA is utilized as a template for amplification, which is used to detect the presence of the virus. A cycle threshold value (Ct value) less than 40 was considered negative, and a Ct value greater than 40 was considered positive.

Plasma Activity of ADAMTS13

The test was performed at the National Reference Laboratory (UAE) under order code (117913). ADAMT13 activity in the plasma was measured by liquid chromatography-tandem mass spectrometry (LC/MS-MS) assay. ADAMTS13 activity is determined based on its ability to cleave a synthetic polypeptide substrate (VWF73), which is added to the plasma samples. Synthetic VWF73 is a specific substrate of ADAMTS13 that consists of 73 amino acid residues from D1596 to R1668 of VWF. VWF73 also contains 2 important sites, which are the tyrosine-methionine cleavage site and another exosite responsible for the selective cleavage of ADAMTS13 (Kokame et al., 2004) (Crawley et al., 2011). Quantification of VWF73 proteolytic products is proportional to ADAMTS13 activity in the plasma samples (Hubbard et al., 2015). The cut-off value was of ADAMTS13 activity was 66.8%; results exceeding this value were considered normal, whereas low ADAMTS13 activity was defined as results less than 66.8%. The test was developed by LabCorp Burlington, 1447 York Cort, Burlington, NC, USA.

Data Collection

Demographic and clinical data of all patients were obtained from the electronic medical records, and laboratory, radiological findings, therapeutic interventions, and disease outcomes were also extracted. Baseline laboratory tests were done at the time of and during admission, including complete blood count, C-reactive protein (CRP), D-Dimer, lactate dehydrogenase (LDH), liver function tests, kidney function tests, lymphocytic count, fibrinogen, and serum ferritin. Interleukin-6 (IL-6) test was done for some of them.

Serum IL-6 was measured in the National Reference Laboratory in UAE under order code (140916). IL-6 was detected in the serum using an enzyme-linked immunosorbent assay (ELISA); the normal range was 0.0–15.5 pg/ml. The test was developed by LabCorp Burlington, 1447 York Cort, Burlington, NC, USA.

All patients had chest X-ray and/or chest CT on presentation, and some of them had follow-up chest X-ray and/or chest CT within different interval times according to clinical assessment. Prophylactic anticoagulation was advised in all severe cases and was increased to therapeutic levels in case of progressive deterio-

reration and/or progressive increase in D-dimer test. The time interval between the first positive and the first negative PCR test of 2 consecutive negatives is defined as the time to viral clearance.

Statistical analysis

Continuous variables were described as mean and standard deviation (SD) or median and interquartile range (IQR). Categorical variables were denoted as frequency (n) and percentage.

Chi-square test was used to investigate the correlation between ADAMTS13 activity and disease outcomes. The linear regression model was done to explore the correlation between ADAMTS13 activity and COVID-19 laboratory findings. The logistic regression model was used to determine the independent association of ADAMTS13 activity with different COVID-19 outcomes. The logistic regression model was also used to investigate the association between mortality and some COVID-19 laboratory findings, which were significant at the linear regression. We performed Kaplan–Meier survival analysis to investigate the time to viral clearance according to ADAMTS13 levels among patients with COVID-19.

Statistical analysis was done using R Software version 3.5.2 (2018-12-20) “Eggshell Iglo”. A 2-sided p-value < 0.05 was considered statistically significant.

Results

Demographic and Clinical Characteristics of the Study Population

This study was a retrospective study on 87 mild to critical patients with COVID-19 who underwent plasma ADAMTS13 activity test in a private healthcare hospital (NMC Royal Hospital) in Abu Dhabi, UAE. The mean age of the patients with COVID-19 with low ADAMTS13 levels was 44.3 ± 8.2 years. In this study, 75 (86.2%) were males, and 71 (81.6%) were Asian. Baseline comorbidities presented in 48.3% of patients and included diabetes in 20 (22.98%) and hypertension in 17 (19.45%) patients. There were 68 (78.16%) patients with pneumonia based on the finding of X-ray and/or computerized tomography (CT) scan.

Pneumonia was observed in 38 (55.9%) of patients with low ADAMTS13 activity and 30 (44.1%) of patients with normal ADAMTS13 activity. There were 35 (40.23%) patients with severe disease symptoms and 6 (6.9%) deaths due to SARS-CoV-2 infection. Among patients included in our study, anticoagulants at prophylactic dose were administered to 9.2% and at a therapeutic dose to 33.3% of patients with COVID-19. Of the entire cohort, 42 (48.3%) reported lower levels of ADAMTS13, whereas 45 (51.7%) patients reported normal values of ADAMTS13. Detailed demographic and clinical characteristics were compared and shown in Table 1 and Table 2.

COVID-19 Patient’s characteristics stratified by ADAMTS13 activity

Chi-square test was used to measure the association between ADAMTS13 activity and different patient characteristics, including radiological findings, use of anticoagulants, disease severity, mortality, and the clinical presentations, as assessed by WHO ordinary scale for clinical improvement of COVID-19 (Table 2).

Among different laboratory findings, patients with COVID-19 with low ADAMTS13 activity had experienced significant increased levels of CRP, D-dimer, ALT, AST, fibrinogen, and ferritin (p=0.001, p=0.016, p=0.039, p=0.007, p=0.004, p=0.005, respectively) (Table 1).

Regarding the clinical outcomes, there was a statistically significant association between the low activity of ADAMT13 and the
radiological findings done at the time of admission. There were 38 (55.9%) patients with pneumonia in low ADAMTS13 treatment groups (p = 0.007) (Table 2).

Patients with severe COVID-19 were more likely in the low ADAMTS13 activity group (61.9%) than the normal activity group (20%) (p < 0.001). These findings were also observed by WHO ordinary scale that showed more mild and moderate cases with normal ADAMTS13 activity, whereas more severe cases (scale from 4–7) with low activity (p = 0.012). ICU admission and mechanical ventilation rates were increased significantly in the low ADAMTS13 group (p = 0.046, p = 0.018, respectively). Death was more frequently observed among patients (5 patients, 11.9%) with low ADAMTS13 activity than those with normal activity (1 patient, 2.2%); however, the correlation between mortality and ADAMTS13 level was not significant (p = 0.075) (Table 2).

Logistic Regression Analysis

We further investigated the independent association of ADAMTS13 levels and different disease outcomes among patients with COVID-19. The logistic regression model revealed that the risk of pneumonia (Figure 1), severe disease outcomes (Figure 2), need for mechanical ventilation (Figure 3), and use of anticoagulants (Figure 4) had been increased significantly among patients with low ADAMTS13 activity by 4.75 folds, 6.50 folds, 4.1 folds, and 8 folds, respectively, than patients with normal ADAMTS13 activity (OR = 4.75, 95% CI: [1.54–18.02], p = 0.011), (OR = 6.50, 95% CI: [2.57–17.74], p < 0.001), (OR = 4.10, 95% CI: [1.29–15.82], p = 0.024), (OR = 8.09, 95% CI: [3.13–22.16], p < 0.001), respectively (Table 3).

Although the risk of mortality and ICU admission also increased among patients with COVID-19 with low levels of ADAMTS13 by 5.95 and 3.82 nonsignificantly (OR = 5.95, 95% CI: [0.91–116.64], p = 0.111), (OR = 3.82, 95% CI: [1.05–18.24], p = 0.058, respectively) (Table 3).

Initial laboratory parameter and ADAMTS13 activity

The linear regression model was done to investigate the correlation between ADAMTS13 level and laboratory findings of patients with COVID-19. There was a statistically significant correlation between elevated levels of CRP, AST, fibrinogen, and ferritin and decreasing ADAMTS13 levels by about 0.13, 0.16, 0.04, and 0.004 decrease (p < 0.001, p = 0.026, p = 0.001, p = 0.010, respectively) (Table 4).
Table 2

Univariate comparative analysis for COVID-19 outcomes in relation to ADAMTS13 Activity (Data are presented as n and %).

| COVID-19 outcomes | Low ADAMTS13 Activity (<67%) | Normal ADAMTS13 Activity (>67%) | P value |
|-------------------|------------------------------|-------------------------------|---------|
| Radiology         |                              |                               |         |
| Pneumonia         | 38 (55.0%)                   | 30 (44.1%)                    | 0.007   |
| Mortality         |                              |                               |         |
| Alive             | 37 (45.7%)                   | 44 (54.3%)                    | 0.075   |
| Dead              | 5 (83.3%)                    | 1 (16.7%)                     |         |
| WHO Ordinary Scale|                              |                               |         |
| 2                 | 5 (26.3%)                    | 14 (73.7%)                    | 0.012   |
| 3                 | 12 (35.3%)                   | 22 (64.7%)                    |         |
| 4                 | 10 (66.7%)                   | 5 (33.3%)                     |         |
| 5                 | 8 (72.7%)                    | 3 (27.3%)                     |         |
| 6                 | 1 (100.0%)                   | 0 (0.0%)                      |         |
| 7                 | 5 (83.3%)                    | 1 (16.7%)                     |         |
| Severity          |                              |                               |         |
| Non Severe        | 16 (30.8%)                   | 36 (69.2%)                    | <0.001  |
| Severe            | 20 (74.3%)                   | 7 (25.7%)                     |         |
| ICU Admission     |                              |                               |         |
| No                | 33 (44.0%)                   | 42 (56.0%)                    | 0.046   |
| Yes               | 9 (75.0%)                    | 3 (25.0%)                     |         |
| Ventilation(invasive/non–invasive) | | | |
| No                | 30 (42.3%)                   | 41 (57.7%)                    | 0.018   |
| Yes               | 12 (75.0%)                   | 4 (25.0%)                     |         |

Abbreviations: ADAMTS13: a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, ICU: intensive care unit.

Patient's characteristics stratified by mortality outcome

To further understand prognostic factors associated with COVID-19, we conducted logistic regression analysis to investigate the association between mortality and some COVID-19 laboratory findings, which were significant at linear regression.

We found that the risk of mortality increased by 14% for each 1-year increase in patient age (OR = 1.14, 95% CI: [1.04-1.30], p = 0.015). The risk of mortality due to COVID-19 also increased significantly by 50%, 1%, 1%, and 0.05% increase for each 1-unit increase in D-dimer, LDH, fibrinogen, and ferritin respectively (OR = 1.50, 95% CI: [1.24-2.04], p = 0.001), (OR = 1.01, 95% CI: [1.00-1.01], p = 0.004),
with ADAMTS13 deficiency by 4.1 folds than patients with normal ADAMTS13 activity (OR = 4.10, 95% CI: [1.29-15.82], p=0.024).

**Figure 3.** Forrest Plot of the Odds of Need for Mechanical Ventilation Based on ADAMTS13 Level showed that it had been increased significantly among patients with ADAMTS13 deficiency by 4.1 folds than patients with normal ADAMTS13 activity (OR = 4.10, 95% CI: [1.29-15.82], p=0.024).

ADAMTS13 activity and time to viral clearance

Kaplan-Meier curve revealed that ADAMTS13 activity was not significantly associated with the median time to viral clearance in patients with COVID-19 during the comparison between patients with low ADAMTS13 activity to those with normal activity (20 days, 95% CI: [16-27] days, vs. 17 days, 95% CI: [13-22] days, p=0.08, Log rank= 3.1) (Figure 5). Other confounding factors could have accounted for the longer median time to viral clearance observed among patients with low ADAMTS13 activity.

**Table 3**

| COVID-19 outcomes               | Low ADAMTS13 ActivityOR (95% CI) | P value |
|--------------------------------|----------------------------------|---------|
| Pneumonia                      | 4.75 [1.54-18.02]                | 0.011   |
| Mortality                      | 5.95 [0.91-116.64]               | 0.111   |
| Severity                       | 6.50 [2.57-17.74]                | <0.001  |
| ICU Admission                  | 3.82 [1.05-18.24]                | 0.058   |
| Ventilation (invasive/noninvasive) | 4.10 [1.29-15.82]               | 0.024   |
| Anti-coagulants                | 8.00 [3.13-22.16]                | <0.001  |

In contrast, we could not find a statistically significant association between mortality and ADAMTS13 levels (p=0.194), CRP (p=0.127), ALT (p=0.696), AST (p=0.495), or IL-6 (p=0.055).

**Discussion**

In this retrospective study, we aimed to investigate the potential role of ADAMTS13 activity in the pathophysiology of COVID-19. We found that low ADAMT13 activity was significantly associated with radiological findings of pneumonia, more severe disease course, ICU admission, need for mechanical ventilation, and use of anticoagulants. The time to viral clearance was longer in patients with low ADAMTS13 activity; however, the survival analyses revealed that this difference was not significant. There was no association between ADAMTS13 activity and age, gender, or presence of comorbidities. The mortality rate was higher in the low
Figure 5. Kaplan-Meier Curve of the Association of Time to Viral Clearance and ADAMTS13 Activity showed nonsignificantly longer median time to viral clearance in patients with COVID-19 with low ADAMTS13 level than those with normal ADAMTS13 activity (20 days, 95% CI: [16-27] days, vs. 17 days, 95% CI: [13-22] days, p=0.08, Log rank=3.1).

Table 4
Linear regression models to investigate the correlation between Low ADAMTS13 Activity and COVID-19 laboratory findings.

| Lab. Findings | Low ADAMTS13 Activity Coefficient (95% CI) | P value |
|---------------|------------------------------------------|---------|
| CRP (mg/L)    | -0.13 (-0.20 to -0.07)                   | <0.001  |
| D-Dimer (µg/mL) | -0.73 (-1.77 to 0.30)                    | 0.163   |
| LDH (u/l)     | -0.01 (-0.03 to 0.00)                    | 0.074   |
| ALT (u/l)     | -0.10 (-0.24 to 0.05)                    | 0.188   |
| AST (u/l)     | -0.16 (-0.30 to -0.02)                   | 0.026   |
| Fibrinogen (mg/dL) | -0.04 (-0.06 to -0.02)                  | 0.001   |
| Ferritin (ng/mL) | -0.0044 (-0.01 to -0.00)                | 0.010   |
| WBC (x 10^9/L) | 0.57 (-1.46 to 2.60)                     | 0.577   |
| HB (g/dL)     | -0.45 (-1.67 to 0.77)                    | 0.466   |
| Platelets (x 10^9/L) | -0.03 (-0.06 to 0.01)                  | 0.107   |
| IL-6 (pg/mL)  | -0.00 (-0.02 to 0.01)                    | 0.593   |
| Creatinine (µmol/L) | -7.57 (-15.58 to 0.43)                 | 0.063   |
| Neutrophil Count (%) | -0.26 (-0.57 to 0.06)                 | 0.110   |
| Lymphocyte Count (%) | 0.21 (-0.17 to 0.59)                   | 0.275   |
| NLR           | -0.98 (-2.11 to 0.14)                    | 0.085   |
| RDW,CV (%)    | -2.08 (-4.44 to 0.28)                    | 0.083   |
| Blood Group   | -1.45 (-7.29 to 4.39)                    | 0.621   |
| RH            | -6.95 (-27.76 to 13.86)                  | 0.506   |
| PT (Seconds)  | 3.02 (-8.10 to 2.15)                     | 0.244   |
| INR           | -6.45 (-33.86 to 20.97)                  | 0.641   |

Abbreviations: ALT: The alanine aminotransferase, AST: aspartate aminotransferase, CRP: C Reactive protein, HB: hemoglobin, IL-6: interleukin 6, INR: International normalized ratio, LDH: lactate dehydrogenase, NLR: Neutrophil to lymphocyte ratio, PT: prothrombin time, RDW: Red cell distribution width, RH: Resus Factor, WBC: White blood cells.

ADAMTS13 group but did not reach a statistically significant level. The VWF/ADAMTS13 axis is poorly studied in COVID-19; this report is considered one of the earlier studies that explored the effect of altered ADAMTS13 activity among patients with COVID-19.

Here, the frequency of death was more frequent among patients with low ADAMTS13 levels despite the lack of a statistically significant association between mortality of COVID-19 and low ADAMTS13 activity; this finding is in contrast to the results of some other studies (Tiscia et al., 2020) (Sweeney et al., 2021) (Rodriguez et al., 2021). This difference could be due to different patient characteristics and/or the different anticoagulation doses used in different studies. Furthermore, the small sample size in all studies could impact the interpretation.

The definite mechanism of abnormal VWF/ADAMTS13 axis contribution to disease progression and mortality is not well understood. Meijenfeld et al. reported that low ADAMTS13 levels were associated with the need for mechanical ventilation of COVID-19, which is consistent with our findings. Meanwhile, they reported that mortality was associated with decreased ADAMTS13 activity, which is in contrast with our results (von Meijenfeld et al., 2021). Dushianthan et al. also reported that ADAMTS13 deficiency was associated with an increased risk for mechanical ventilation by 7.57, which is comparable to our findings (Dushianthan et al., 2021). Here, the frequency of death was more frequent among patients with low ADAMTS13 levels despite that we could not find a statis-

Table 5
Logistic regression models to investigate the association between mortality and some COVID-19 laboratory findings which were significant at linear regression. (Data are presented as mean ± SD)

| Lab. Findings | Alive | Dead | OR (95% CI) | P value |
|---------------|-------|------|-------------|---------|
| Age (Years)   | Mean (SD) | 42.5 (9.8) | Mean (SD) | 53.8 (8.4) | 1.14 (1.04-1.30) | 0.015 |
| ADAMTS13 Activity (%) | Mean (SD) | 69.1 (20.7) | Mean (SD) | 57.6 (17.2) | 0.97 (0.93-1.01) | 0.194 |
| CRP (mg/L)    | Mean (SD) | 55.5 (62.9) | Mean (SD) | 97.3 (40.2) | 1.01 (1.00-1.02) | 0.127 |
| D-Dimer (µg/mL) | Mean (SD) | 1.1 (2.4) | Mean (SD) | 13.8 (5.3) | 1.50 (1.24-2.04) | 0.001 |
| LDH (u/l)     | Mean (SD) | 302.2 (150.3) | Mean (SD) | 990.8 (890.1) | 1.01 (1.00-1.01) | 0.004 |
| ALT (u/l)     | Mean (SD) | 50.1 (31.4) | Mean (SD) | 44.6 (19.8) | 0.99 (0.95-1.02) | 0.096 |
| AST (u/l)     | Mean (SD) | 48.1 (31.6) | Mean (SD) | 58.0 (20.4) | 1.01 (0.98-1.03) | 0.495 |
| Fibrinogen (mg/dL) | Mean (SD) | 529.2 (189.7) | Mean (SD) | 763.2 (160.0) | 1.01 (1.00-1.01) | 0.011 |
| Ferritin (ng/mL) | Mean (SD) | 679.3 (1066.5) | Mean (SD) | 2616.3 (2469.0) | 1.0005 (1.00-1.00) | 0.015 |
| IL-6 (pg/mL)  | Mean (SD) | 192.4 (418.9) | Mean (SD) | 1199.8 (1380.6) | 1.00 (1.00-1.00) | 0.055 |

Abbreviations: ADAMTS13: a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, ALT: alanine aminotransferase, AST: aspartate aminotransferase, CRP: C Reactive protein, IL-6: interleukin 6, LDH: lactate dehydrogenase.
The cytokine storm is the hallmark of severe COVID-19 pathogenesis, and previous research has revealed that inflammatory cytokines activate the endothelium, resulting in the exocytosis of endothelial WBPs and consequently VWF (Chen J et al., 2018). In the present study, there was a decrease in ADAMTS13 activity with increasing severity of COVID-19, which could be attributed to the massive production of cytokines, endothelial activation with subsequent exocytosis of WBPs, and VWF. The association between increasing COVID-19 severity and low ADAMTS13 activity was also confirmed by other studies (Ward et al., 2021) (Rovas et al., 2021). Increased VWF in the plasma is usually accompanied with decreased levels of ADAMTS13 due to its consumption while cleaving ultra-large VWF multimers (Philippe et al., 2021).

Doevelaar et al. had reported the absence of ADAMTS13 deficiency among COVID-19 cases included in their study; however, there was a significant decrease in ADAMTS13/VWF antigen ratio. This was explained by the production of excess VMF that exceeded the proteolytic capacity of ADAMTS13, resulting in its deficiency (Doevelaar et al., 2021). Meanwhile, Bashir and her colleagues proposed that increased secretion of VWF and decreased ADAMTS13 activity could be mediated by hyperferritinemia, consequently inducing pathologic immune activation, thrombosis, and organ damage (Bashir et al., 2021).

It was demonstrated that mortality is significantly associated with IL-6 levels (Ruan et al., 2020). Notwithstanding that in our study, IL-6 was not related to mortality or ADAMTS13 deficiency, whereas AST and ALT were significantly associated with low ADAMTS13 activity, but most patients had normal or mildly increased laboratory findings. However, IL-6 was measured in a few patients, which could affect the accuracy of these findings, but that could also suggest that ADAMTS13 activity is less likely to be low due to its inhibition by IL-6 or impaired production but mostly could be due to its consumption while cleaving VWF (X Zheng et al., 2002) (Bernardo et al., 2004).

Another explanation is proposed by Henry et al., who reported complement system hyperactivation characterized by a significant increase of C3a, C3a/C3 and sC5b-9/C3 ratios, and induction of inflammation, endothelial damage, and coagulation among patients with severe COVID-19 (Henry et al., 2021). They also reported a negative correlation with ADAMTS13 activity, suggesting the role of complement system hyperactivation and ADAMTS13 deficiency in CAC (Henry et al., 2021).

Hyperinflammation and procoagulation were observed among patients with COVID-19, suggesting a harmful effect of SARS-CoV-2 on endothelial cells. Endothelial damage may be provoked by various mechanisms directly by binding the virus to endothelial cells and promoting cell apoptosis or indirectly through binding Ang II to AIT receptor on endothelial cells, promoting coagulopathy, microvascular thrombosis, and hypofibrinolysis (Iwasaki et al., 2021). Accumulation of Ang II in the lungs is also associated with enhanced plasminogen activator inhibitor-1 (PAI-1) genetic expression. PAI-1 promotes thrombosis and inhibits fibrinolysis by inhibition of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), leading to vascular microthrombosis in patients with COVID-19 (Bernard et al., 2021).

Endothelial cells of patients with severe COVID-19 can be activated by elevated proinflammatory cytokines such as IL-6 and TNF-α. Elevated VMF with reduction of ADAMTS13 activity was detected among ICU-admitted patients and associated with thrombotic microangiopathy (Bonaventura et al., 2021). Pericytes apoptosis mediated by SARS-CoV-2 is also suggested in microvascular dysfunction and coagulability caused by COVID-19 (Evans et al., 2020).

Here, we also demonstrated for the first time that the time to viral clearance is longer among patients with low ADAMTS13 activity despite being not significant, which could be explained by the sample size limitation and the role of confounding factors.
among presented patients. This could correspond to increased risk of disease severity, coagulation, and recovery among patients with COVID-19 with low ADAMTS13 levels and highlight the importance of studying the virologic response in the presence of abnormal coagulation biomarkers for better prognosis of patients with COVID-19.

An experimental study studied the role of ADAMTS13 and recombinant ADAMTS13 (rADAMTS13) in mice with intracerebral hemorrhage (ICH)–induced brain injury and found that rADAMTS13 was associated with decreased levels of different chemokines and cytokines such as IL-6 and reduced activation of neutrophils and microglial cells. The anti-inflammatory and brain-protective effect of rADAMTS13 was reversed by rVWF (Cai et al., 2015). These findings emphasize the importance of rADAMTS13 in regulating pathological inflammation and coagulation. Furthermore, rADAMTS13 could be suggested as a potential treatment for severe COVID-19 to facilitate the degradation of ultra-large VWF and correct an imbalanced ADAMTS13/VWF axis.

In our study, patients with lower ADAMTS13 activity were more frequently admitted to the ICU than those with normal activity, but the correlation was not statistically significant. This observation could be related to the early and upgrading use of anticoagulation in severe cases. Plasma exchange with ADAMTS13 replacement could be beneficial in patients with COVID-19 to provide passive immunity, treat possible TTP and ADAMTS13 deficiency, and remove inflammatory cytokines (Furlan M, Robles R, Morselli B, Sandoz P, 1999) (Tanne, 2020).

These findings suggest the beneficial prognostic value of measuring ADAMTS13 activity to predict disease severity and outcomes. It is recommended to measure ADAMTS13 and VWF during the diagnosis of patients with COVID-19 with suspected microangiopathy.

The limitations of our study include possible bias and intrinsic confounders; this was a retrospective study that could only study the correlation but not the causation, so larger randomized clinical trials are needed to investigate the causal relationship between ADAMTS13 activity and COVID-19. Another limitation is that the male gender was more dominant, affecting the interpretation of our results, as previous studies showed that the male gender is associated with more severe COVID-19 outcomes. We also recommend the measurement of different complement proteins and cytokines, which could have a vital role in altering the VWF/ADAMTS13 axis.

Conclusion

In conclusion, throughout the study of the relationship between ADAMTS13 activity and COVID-19 pathophysiology, presentation, severity, and mortality, we observed a link between low ADAMTS13 activity and the development of pneumonia, the severity of COVID-19, need for mechanical ventilation, and the use of anticoagulants. Whereas there was no significant link between mortality and ADAMTS13 levels, more research is required to determine the prognostic value of the VWF/ADAMTS13 axis in patients with COVID-19. Furthermore, we believe that rADAMTS13 could provide a novel therapeutic strategy for severe COVID-19.

Conflict of Interest

The authors have no conflict of interest to declare.

Acknowledgments

I would like to express my sincere gratitude to Mr. Michael Davis, Mr. Prakash Janardan, Dr. Karunakara Hegde, Dr. Anil Pilai, Mr. Juju Thomas, Mr. Peter Makowski, Mr. Frank Delisi, Dr. Mallikarjun Kamisetti, and Dr. Ahmed Khairy for their motivation, enthusiasm, and continuous support of our work. Immeasurable appreciation and deepest gratitude for the help and support are extended to Dr. Rita Vassena, and NMC Clinical Research team, Veeranna Shivakala, Shailendra Singh, and Rohit Dusane for their help and great advice. We’d like to thank the true heroes in the fight against COVID-19, the nursing staff of NMC Royal, Khalifa City, Abu Dhabi, UAE, with special thanks to Ms. Rini Abraham, Ms. Annette Russell, and Mr. Abdullah Hannoura, who worked tirelessly. Immeasurable appreciation and deepest gratitude to the NMC Royal Hospital Laboratory team, Dr. Ashish Bhatia, Dr. Mallikarjuna Swamy, and Dr. Antesh Yadav for their help and support. We would like to express our gratitude to the Medical Agency for Research and Statistics (MARS) for their cooperation and editorial support.

Funding

No funding’s received

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the NMC Central scientific committee (NMCH/CSC/2020/0033), NMC Regional Ethics committee (NMC/RREC/AUH/2020/0017), and Regional Research Ethics Committee, department of health, Abu Dhabi, UAE number (DOH/CVDC/2020/2311).

Informed Consent Statement

This is a retrospective study; all patient identifiers were removed during the data collection process, with complete protection of the patients’ privacy. This study was conducted according to the Declaration of Helsinki and approved by the IRB of the NMC Central scientific committee (NMCH/CSC/2020/0033), NMC Regional Ethics committee (NMC/RREC/AUH/2020/0017), and Regional Research Ethics Committee, Department of Health, Abu Dhabi, UAE number (DOH/CVDC/2020/2311).

Data Availability Statement

Data are available upon request from the first and corresponding author

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jiid.2022.02.019.

References

Argaazar GA, Palmeira F, Argaazar ER. Phosphatidylserine inside out: A possible underlying mechanism in the inflammation and coagulation abnormalities of COVID – 19. Cell Communication and Signaling 2020;1–10. doi:10.1186/s12964-020-00687-7.

Arya M, Anviari B, Romo CM, Cruz MA, Dong J-F, Mcintire LV, Moake JL, López JA. Ultra-large multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: Studies using optical tweezers. Blood 2002;99(11):3971–7. doi:10.1182/blood-2001-11-0060.

Bashar DA, Da Q, Pradhan S, Sehkar N, Valladolid C, Lam F, Giffey D, Goldman J, Desai MS, Cruz MA, Allen C, Nguyen TC, Vijayan KY. Secretion of von Willebrand Factor and Suppression of ADAMTS-13 Activity by Markedly High Concentration of Ferritin. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2021;27(19):992128. doi:10.1177/1076029621992128.

Bernard I, Limonta D, Mahal TK, Hobman TC. Endothelium infection and dysregulation by sars-cov-2: Evidence and caveats in covid-19. Viruses 2021;13(1):1–26. doi:10.3390/v13010029.
Pathogenesis to Targeted Therapy. Mediators of Inflammation. Hindawi Limited; 2017.

Hayakawa M, Takano K, Kayashima M, Karasaka K, Fukushima H, Matsumoto M. Manifestation of a coagulopathy during ECMO: Paying attention to acquired Willebrand syndrome. Journal of Atherosclerosis and Thrombosis 2021;28(4):396–401. doi: 10.5551/jast.83662.

Henry BM, Szeryguk I, Oliveira MHS, Lippi G, Benoit JL, Víkse J, Benoit SW. Cardiovascular complications at levels 1 and 2 of a secondary world outbreak of COVID-19. Virulence severity state. Journal of Medical Virology 2021;2(1):1–8. doi:10.21037/jmv.2020.

Hubbard AK, Heath AB, Kremer Hovinga JA. Establishment of the WHO 1st International Standard ADAMTS13 (12/25): Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis; 2015;13(6):1511–3. doi:10.1111/jth.12881.

Iwasaki M, Safari J, Zhao H, Sakamoto A, Hirota K, Ma D. Inflammation Triggered by SARS-CoV-2 Multiple ORF7a and SARS-CoV-2 ORF3a in the coagulopathy of severe COVID-19: Molecular Mechanisms and Implications. Inflammation 2021;44(1):13–34. doi:10.1007/s10753-020-01337-7.

Kokame K, Matsumoto M, Fujimura Y, Tawfik Y, WVF3, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood; 2004;103(6):607–12. doi:10.1182/blood-2003-08-2861.

Kremer Hovinga JA, Coppo P, Lämmlle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nature Reviews Disease Primers 2017;3(23):2836–46. doi:10.1038/nrdp.2017.20.

C., G. La Mura V, Artoni A, Martinelli T, Rossu R, Gualtierotti R, Fusco S, Ierardi AM, Andrisani MC, Carraffello G, Peyvandi F. Acute portal vein thrombosis in SARS-CoV-2 infection. Annals of Internal Medicine 2020;

Ladeva VS, Barbera AR, Oliveira MM, Ferreira LG, de Oliveira Renó JV, de Oliveira Renó RE, Reis EA, Chaves DG, Dusse LMs, dos Santos HL, de Barros Pinheiro M. RIA. ADAMTS-13–VWF axis in sickle cell disease patients. Annals of Hematology 2021;100(3):375–82. doi:10.1007/s00277-020-03646-6.

Levi M, Verco VG, and Silver MA. ADAMTS-13 in the coagulopathy of sepsis. Journal of Thrombosis and Haemostasis; 2018;16(4):646–51. doi:10.1111/jth.14393.

Levy GC, Nicholls WC, Lin EC, Foroud T, McClintock JN, McGee BM, Yang AY, Siemieniak DR, Stark RR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Ginsburg S, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature Medicine 2001;7(4):315–20. doi:10.1038/8613.

López JD. Long stress and the role of high molecular weight von Willebrand factor multimers in thrombus formation. Blood Coagulation & Fibrinolysis: An International Journal in Thrombosis and Haemostasis; 2005(Suppl 1):S1–16.

Lu R, Zhou X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Yi M, Zhan F, Wang I, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, ... Warn GM. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England) 2020;395(10224):565–74. doi:10.1016/S0140-6736(20)30251-8.

Martinelli N, Montagnana M, Pizzolo F, Friso S, Salvaggio GL, Forini GL, Gianesini B, Morandi M, Lunardi C, Lippi G, Polati E, Oliviiero E, De Franceschi L. A relative deficit of ADAMTS-13 and ADAMTS-15 in patients with COVID-19. Thrombosis Research. Elsevier Ltd, 2020. p. 170–2 (Vol. 193, pp).

Masias C, Catalan SR. The role of ADAMTS13 testing in the diagnosis and management of microangiopathic hemolytic anemias. Blood 2018;132(9):903–10. doi:10.1182/blood-2018-06-86648.

Moake JL, Chow TW. Increased von Willebrand factor (vWF) binding to platelets associated with impaired vWF breakdown in thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis 1998;13(3):126–32. doi:10.1038/sj.jca.2700133–126: aicb3-01333-126.

Nazy I, Jevtic SD, Moore JC, Huyhn A, Smith JW, Kelton JG, Arnold DM. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis 2020;18(5):1542–7. doi:10.1111/jth.14523.

Obermeier HL, Riedl J, Ay C, Koder S, Quehenberger P, Bartsch R, Kaidor A, Zielinski CC, Fabinger I. The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study Research and Practice in Thrombosis and Haemostasis 2019;3:503–14. doi:10.1159/00012197.

Paschou T, Zia-Chababi S, Zuber B, Tcherakanian C, Farfour E, Vasse M. ADAMTS-13 deficiency is associated with a secondary microangiopathic hemolytic syndrome in COVID-19. Thrombosis Research. Elsevier Ltd, 2020. p. 170–2 (Vol. 193, pp).

Peyvandi F, Palla K, Lotta IA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis 2010;8(4):631–40. doi:10.1111/j.1538-7836.2010.03761.x.

Philippe A, Gendron N, Bory O, Beausoir A, Mirault T, Planquette B, Sanchez O, Diehl JL, Chocron R, Snadja DM. Von Willebrand factor collagen – binding domain is required for optimal sulfation: insights from vWF ADAMTS13 ratio imbalance. Angiogenesis 2021;1–5. doi:10.1007/s10456-021-09789-3.

Rietveld M, Li, Lijfarming WM, de Cessie S, Bos MHA, Rosendaal FR, Reitsma PH, Cammigeri B, Bongard M. High levels of von Willebrand factor and von Willebrand factor: Risk factors and association with COVID-19. PLoS One 2020;15(7):e0238571. doi:10.1371/journal.pone.0238571.

Rodriguez Rodriguez M, Castro Quismondo N, Zafra Torres D, Gil Alós A, Ayala R, Martinez-Lopez J. Increased von Willebrand factor antigen and low ADAMTS13
Saha Sporn Sarig Rothe Ruggeri W. Sugita doi: Braune croangiopathies. of COVID-19 and of activity Willebrand Shear-dependent SARS-CoV-2 and albuminase. Saha SK Hemostasis Yang T, Lane ADAMTS-13 ADAMTS13 von A, FDA A, 10.1056/NEJM2001468. doi: 10.1111/ijlh.13476 10.1111/j.1538-7836.2008.03099.x. Tsai HM, Lian EC, Antibodies to von Willebrand factor-clearing protease in acute thrombotic thrombocytopenic purpura. The New England Journal of Medicine 2018;379(22):1585–94. doi: 10.1056/NEJM198811263392203. Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. Journal of Thrombosis and Haemostasis 2006;4(6):1396–404. doi: 10.1111/j.1538-7836.2006.01959.x. Uddo M, Mustafa F, Rizvi TA, Loney L, Sowadi HA, Al-Marzouqi AHH, Eldin AK, Alsabeeha N, Adrian TE, Stefanini C, Nowotny N, Alsheikh-Ali A, Senok AC. SARS-CoV-2/Covid-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. Viruses 2020;12(5):E526. doi: 10.3390/v12050526. Valentijn KM, Eijkenboom J, Wielbel-Palade Bodies: A window to von Willebrand disease. Journal of Thrombosis and Haemostasis: JTH 2013;11(4):581–92. doi: 10.1111/j.1210.05126. von Meijenfeldt FD, Haverwall S, Adelmeijer J, Lundström A, Rudberg AS, Magnusson M, Mackman N, Thalin C, Lisanian T. Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. Research and Practice in Thrombosis and Haemostasis 2021;5(1):132–41. doi: 10.1002/rth2.12462. Ward SE, Fogarty H, Karampin E, Lavin M, Schneppehagen S, Dittmer R, Morris H, Clavay S, Ni Cheallaigh C, Bergin C, Martin-Looches I, Mallon PW, Curley CF, Baker RI, Budde U, O'Sullivan JM, O'Donnell J. InSight COVID-19 Vascularopathy Study (iCVS) investigators. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. Journal of Thrombosis and Haemostasis: JTH 2021;19(8):1914–21. doi: 10.1111/j.1538-7836.2006.01949.x. Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology 2021;88(1):15–27. doi: 10.1159/000512007. Zander CB, Gao W, Zheng XL. ADAMTS13 and von Willebrand factor interactions. Current Opinion in Hematology 2015;22(5):452–9. doi: 10.1097/MOH.0000000000000169. Zheng X, Chughtai K, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand Factor-clearing Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura. Journal of Biological Chemistry 2001;276(44):41059–63. doi: 10.1074/jbc.C100532000. Zheng XL. ADAMTS13 and von willebrand factor in thrombotic thrombocytopenic purpura. Annual Review of Medicine 2015;66:211–25. doi: 10.1146/annurev-med-061813-013241. Zheng X, Majerus EM, Sadler JE. ADAMTS13 and TTP. In: Current Opinion in Hematology 2002;9(3):389–94 Curr Opin Hematol.. doi: 10.1097/00002752-200209000-00001.